CASP3 and prostate carcinoma: NU9056 treatment inhibited cellular proliferation in a panel of prostate cancer cell lines (50% growth inhibition, 8–27 μM) and induced apoptosis via activation of caspase 3 and caspase 9 in a concentration- and time-dependent manner.